Concepedia

Author

James A. Bolognese

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

Bolognese, James A., J A Bolognese, J Bolognese, J. A. Bolognese, J. Bolognese, J.A Bolognese, J.A. Bolognese, James A Bolognese, James A. Bolognese, James Bolognese

96

Publications

7.5K

Citations

32

H-Index

113

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)Cytel (United States)United States Military AcademyUniversity of Southern CaliforniaUniversity of Washington
JA

About

James A. Bolognese is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

18

22

2.5K

2

Health Sciences

6

6

232

3

Engineering

3

3

63

4

Natural Sciences

2

2

36

5

Public Health

2

2

92

James A. Bolognese

×

51

Publications

7.1K

Citations

30

H-Index

YearCitations

Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial

Robert S. Bresalier, Robert S. Sandler, Hui Quan,

New England Journal of Medicine

2005

2.5K

Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison

Christopher P. Cannon, Sean Curtis, Garret A. FitzGerald,

The Lancet

2006

520

A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2–specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis

Loren Laine, S. E. Harper, Thomas Simon,

Gastroenterology

1999

476

Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis.

Elliot Ehrich, Gareth Roderique‐Davies, David J. Watson,

PubMed

2000

433

A Randomized Trial of Rofecoxib for the Chemoprevention of Colorectal Adenomas

John A. Baron, Robert S. Sandler, Robert S. Bresalier,

Gastroenterology

2006

431

Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial

Christopher J. Hawkey, Loren Laine, Thomas Simon,

Arthritis & Rheumatism

2000

365

Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers.

Jonathan A. Tobert, G. D. Bell, J Birtwell,

Journal of Clinical Investigation

1982

205

A randomized, phase 2 study investigating TRV130, a biased ligand of the μ-opioid receptor, for the intravenous treatment of acute pain

Eugene R. Viscusi, Lynn R. Webster, Michael E. Kuss,

Pain

2015

200

Specific inhibition of cyclooxygenase‐2 with MK‐0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen

Frank L. Lanza, M F Rack, Thomas Simon,

Alimentary Pharmacology & Therapeutics

1999

170

Response relationship of VAS and Likert scales in osteoarthritis efficacy measurement

James A. Bolognese, Thomas J. Schnitzer, Elliot Ehrich

Osteoarthritis and Cartilage

2003

137

Page 1